311
Participants
Start Date
March 1, 2012
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
tapering or discontinuation of etanercept
Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS\<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
Affiliated Hospital of Jiaxing University
OTHER
Shaoxing Second Hospital
OTHER
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Wenzhou Central Hospital
OTHER
Zhejiang Provincial People's Hospital
OTHER
Shaoxing People's Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER